4821-88-9

Basic information

• Product Name: 6,7-Dimethoxyphthalazin-1(2H)-one
• Synonyms: 6,7-Dimethoxyphthalazin-1(2H)-one;m-Opiazone;6,7-DiMethoxy-2H-phthalazin-1-one;6,7-dimethoxy-1,2-dihydrophthalazin-1-one
• CAS NO: 4821-88-9
• Molecular Formula: C₁₀H₁₀N₂O₃
• Molecular Weight: 206.2
• Mol File: 4821-88-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 6,7-Dimethoxyphthalazin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-Dimethoxyphthalazin-1(2H)-one(4821-88-9)
• EPA Substance Registry System: 6,7-Dimethoxyphthalazin-1(2H)-one(4821-88-9)

Safety Data

• Hazardous Substances Data: 4821-88-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

Different sources of media describe the Uses of 4821-88-9 differently. You can refer to the following data:
1. M-Opiazone is used in the preparation of cinnoline and phthalazine derivs and used as phosphodiesterase 10 inhibitors.
2. Used in the preparation of cinnoline and phthalazine derivs. as phosphodiesterase 10 inhibitors.

Upstream product

• 531-88-4 5,6-dimethoxyphthalide 
• 93-07-2 Veratric acid 
• 40125-46-0 3-BROMO-5,6-DIMETHOXY-PHTHALIDE 
• 490-63-1 2-formyl-4,5-dimethoxybenzoic acid 

Downstream Products

• 70724-23-1 1-chloro-6,7-dimethoxyphthalazine 

Relevant articles and documents

Synthesis, biological evaluation and molecular modeling studies of phthalazin-1(2: H)-one derivatives as novel cholinesterase inhibitors

A new series of donepezil analogues based on the phthalazin-1(2H)-one scaffold was designed and synthesized with the aim of exploring its potential as human ChEIs. Biological results revealed that the structural modifications proposed significantly affected ChE inhibitory potency as well as selectivity for AChE/BuChE. Compound 1d showed promising in vitro inhibition of both enzymes in the μM range. However, most target compounds were significantly more active against AChE than BuChE, specifically 1f, 1h and 1j, with IC50 values in the low micromolar or submicromolar range, the most active compounds in the series. Docking simulations suggested that the most active compounds can recognize the donepezil binding site using a similar interactions network. These results allowed us to rationalize the observed structure-activity relationships. Moreover, the predicted physicochemical and ADME properties were also comparable to those of donepezil.

Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines

1-(3- or 4-substituted piperidino)phthalazines of the formula wherein R is C1-6 alkyl; Y is a 3- or 4-position substituent and is -X-(CHR1)m-Z wherein R1 is hydrogen or C1-6 alkyl; m is 1 or 2; X is oxygen or a direct link provided that when m is 1, X is a direct link; and Z is -N(R2)COR3, -N(R2)COOR3, -N(R2)SO2R3, -N(R2)SO2NR4R5, -N(R2)SOR3, -N(R2)CONR4R5 or -OCONR4R5, wherein R2 and R5 are each independently hydrogen or C1-6 alkyl; R3 is C1-6 alkyl, phenethyl, benzyl, C3-7 cycloalkyl, phenyl or pyridyl; R4 is hydrogen or R3; provided that when X is a direct link, R3 or R4 is C3-7 cycloalkyl; the pharmaceutically acceptable acid addition salts thereof; processes for their preparation; and their use as cardiac stimulants and phosphodiesterase inhibitors